Meridian Co., Ltd.
OTC Bulletin Board : MRDAF

Meridian Co., Ltd.

November 15, 2007 09:00 ET

Meridian Co., Ltd. Receives Health Canada Approval for LAPEX 2000 LipoLaser-A Revolutionary New Device for Painless Fat Reduction & Body Contouring

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 15, 2007) - Meridian Co. Ltd. (OTCBB:MRDAF) announced today that it has received regulatory approval from Health Canada to market its LAPEX 2000 LipoLaser System (LipoLaser) in Canada. The LipoLaser will be marketed in Canada for girth loss, body contouring, and the reduction in the appearance of cellulite.

"The LipoLaser's ability to deliver instant results sets it apart from the rest of the aesthetic devices available today," said Anna Brazier, President of Meridian Medical, Inc., the exclusive North American distributor for LipoLaser. "Our patent pending Body Forming Technology directly targets stubborn fat cells in a non-invasive way."

Equivalent to a United States Food and Drug Administration (FDA) clearance, Health Canada's license number assignment makes the LipoLaser available immediately for sale and use throughout all provinces and territories in Canada. Doctors or patients interested in receiving more information can call: 1-877-738-8119.

More About: LAPEX 2000 LipoLaser

The LAPEX 2000 LipoLaser was designed to target the medical and aesthetic market, specifically to address body contouring, girth loss, spot fat reduction, and reduction in the appearance of cellulite. The LAPEX 2000 LipoLaser's non-invasive treatment is considered one of the most innovative methods to treat those stubborn areas of fat. The demand for this type of treatment is expected to grow rapidly, not only in the plastic surgery profession but in any clinical setting such as medi-spas and wellness centers.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing and sales of advanced medical devices in the healthcare industry. With a dynamic research and development team, Meridian is at the forefront in the development of cutting edge medical technologies. The Company presently holds a total of 18 worldwide patents on its technology, and has received FDA approval and Health Canada approval as well as other international regulatory approvals, for many of its products. Meridian has over 1500 clients including physicians, hospitals, clinics, healthcare professionals, and wellness centers in Korea, USA, Canada, China, Japan and Europe, and continues to successfully market its superior product line to a growing number of clients worldwide.

On Behalf of the Board of Directors, Hyeon Seong Myeong President

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the Company.

Contact Information